Home >> News >> Business >> Global Asthma And COPD Drugs Market Is Expected To Reach US$ 56.5 Bn By 2025

Global Asthma And COPD Drugs Market Is Expected To Reach US$ 56.5 Bn By 2025

According to the latest market report published by Credence Research, Inc. “Asthma and COPD Drugs Market – Growth, Future Prospects, and Competitive Analysis, 2017 – 2025,” the global asthma and COPD drugs market was valued at US$ 39,021.2 Mn in 2016, and is expected to reach US$ 56,507.7 Mn by 2025, expanding at a CAGR of 4.2% from 2017 to 2025.

The report includes forecast and analysis for the Asthma And COPD Drugs market on a global and regional level. The research gives important data of 2016, 2017 and 2018 along with a projection from 2018 to 2026 based on revenue. The study covers drivers and limitations of the Asthma And COPD Drugs market along with the impact they have on the trade over the forecast period. Additionally, the report covers the study of possibilities available in the Asthma And COPD Drugs market on a global level.

Browse full report:

https://www.credenceresearch.com/report/asthma-and-copd-drugs-market

Request for Customization: https://www.credenceresearch.com/request-for-customization/58486

Market Insights

Globally, asthma and COPD is one the leading chronic respiratory diseases, with high prevalence and increasing health care and economic burden. Thus, disease represent a lucrative market for pharmaceutical companies. COPD is rated to be the fourth most common cause of mortality, and expected to reach third position by 2030, in case the risk such as smoking, pollution is not addressed. Gradually over the period of time the treatment of asthma and COPD shows improvement, with novel drugs and treatment strategies, along with usage of non-pharmacologic treatment. It has being observed there is being surge in prevalence of asthma and COPD in developed and developing countries. In developed countries, there is being rise in prevalence of asthma due to lifestyle changes in terms of food habit, low level of exercise, etc., while in developing countries the prevalence is due to pollution and smoking.

The global asthma and COPD drugs market is segmented by drug type into anti-inflammatory drugs, bronchodilator monotherapy and combination drugs. Anti-inflammatory drugs includes corticosteroids, anti-leukotrienes and monoclonal antibodies. Bronchodilator monotherapy includes short-acting beta2-agonist (SABAs) and long-acting beta2-agonist (LABAs) and anticholinergic drugs. Amongst all, combination therapy of long-acting beta2 agonist (LABA)/ inhaled corticosteroid (ICS) dominates the market. The combination therapy that include Symbicort (AstraZeneca), Advair (GlaxoSmithKline) is most preferred treatment against asthma/ COPD, due to better efficacy and less side effects.

As of the current market scenario, North America together dominate the global asthma and COPD drugs market followed by the European market. Rising prevalence of asthma and COPD due to pollution, change in lifestyle, entry of generics and novel therapies in the market. Asia Pacific is anticipated to be the fastest growing market for the forecast period. Emerging economies such India, China due to industrialization, demographic changes, urbanization there is been rise in pollution thus increase in prevalence of asthma and COPD population.

Market Competition Assessment:

Key players in the global asthma and COPD drugs market are Novartis AG, Merck & Co, GlaxoSmithKline Plc, Boehringer Ingelheim Gmbh, Nycomed, Abbott Laboratories, AstraZeneca, Roche Holding AG, Teva Pharmaceutical Industries, Vectura Group, Pfizer Inc. and others.

Global Asthma and COPD Market, By Geography, 2015-2025 (US$ Mn)
5.1 Preface
5.2 North America (U.S. & Canada)
5.3 Europe (U.K., Germany & Rest of Europe)
5.4 Asia Pacific (China, Japan, & Rest of APAC)
5.5 Latin America (Brazil, Mexico & Rest of LATAM)
5.6 Middle East and Africa (UAE, Saudi Arabia, South Africa)

Chapter 6 Company Profiles
6.1 Novartis AG
6.2 Merck & Co
6.3 Glaxosmithkline Plc
6.4 Boehringer Ingelheim Gmbh
6.5 Nycomed
6.6 Abbott Laboratories
6.7 AstraZeneca
6.8 Roche Holding AG
6.9 Teva Pharmaceutical Industries
6.10 Vectura Group
6.11 Pfizer Inc.

Request a Sample of Asthma And COPD Drugs Market research report from – https://www.credenceresearch.com/sample-request/58486

Reasons for Buying Asthma And COPD Drugs market:

This report provides pin-point analysis for changing competitive dynamics

It provides a forward looking perspective on different factors driving or restraining market growth

It provides a six-year forecast assessed on the basis of how the market is predicted to grow

It helps in understanding the key product segments and their future

It provides pin point analysis of changing competition dynamics and keeps you ahead of competitors

It helps in making informed business decisions by having complete insights of market and by making in-depth analysis of market segments

Thanks for reading this article; you can also get individual chapter wise section or region wise report version like North America, Europe or Asia.

Do You Have Any Query or Specific Requirement? Ask to Our Industry Expert @ https://www.credenceresearch.com/inquiry-before-buying/58486

About Us

Credence Research is a worldwide market research and counseling firm that serves driving organizations, governments, non-legislative associations, and not-for-benefits. We offer our customers some assistance with making enduring enhancements to their execution and understand their most imperative objectives. Over almost a century, we’ve manufactured a firm extraordinarily prepared to this task.

Media Contact

Company Name: Credence Research, Inc.

Contact Person: Chris Smith, Global Sales Manager

Email: sales@credenceresearch.com

Phone: +1-800-361-8290

Address: 105 N 1st ST #429, SAN JOSE, CA 95103 US

City: SAN JOSE

State: California

Country: United States

Website: https://www.credenceresearch.com/

Leave a Reply

Your email address will not be published. Required fields are marked *